Literature DB >> 10435956

Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study.

M Schlegel1, J J Osterwalder, R L Galeazzi, P L Vernazza.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10435956      PMCID： PMC32261          DOI： 10.1136/bmj.319.7206.352

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

Review 1.  Immunisation and herd immunity.

Authors:  R M Anderson; R M May
Journal:  Lancet       Date:  1990-03-17       Impact factor: 79.321

2.  Field evaluation of the clinical effectiveness of vaccines against pertussis, measles, rubella and mumps. The Benevento and Compobasso Pediatricians Network for the Control of Vaccine-Preventable Diseases.

Authors: 
Journal:  Vaccine       Date:  1998-05       Impact factor: 3.641

3.  Expanded programme on immunization. Immunization coverage against measles, mumps and rubella.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  1993-03-19

4.  An outbreak of mumps in a population partially vaccinated with the Rubini strain.

Authors:  D Germann; A Ströhle; K Eggenberger; C A Steiner; L Matter
Journal:  Scand J Infect Dis       Date:  1996

5.  The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.

Authors:  H Peltola; O P Heinonen; M Valle; M Paunio; M Virtanen; V Karanko; K Cantell
Journal:  N Engl J Med       Date:  1994-11-24       Impact factor: 91.245
  5 in total
  22 in total

Review 1.  Concerns about immunisation.

Authors:  H Bedford; D Elliman
Journal:  BMJ       Date:  2000-01-22

2.  MMR vaccine--worries are not justified.

Authors:  D A Elliman; H E Bedford
Journal:  Arch Dis Child       Date:  2001-10       Impact factor: 3.791

3.  Comparison between indirect immunofluorescence assay and shell vial culture for detection of mumps virus from clinical samples.

Authors:  Jordi Reina; Francisca Ballesteros; Enrique Ruiz de Gopegui; Maria Munar; Margarita Mari
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

4.  Factors influencing preclinical in vivo evaluation of mumps vaccine strain immunogenicity.

Authors:  B Halassy; T Kurtović; M Brgles; M Lang Balija; D Forčić
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Assessment of mumps virus-specific antibodies by different serological assays: which test correlates best with mumps immunity?

Authors:  R Allwinn; B Zeidler; K Steinhagen; E Rohwäder; S Wicker; H F Rabenau; H W Doerr
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-01       Impact factor: 3.267

6.  Safety and immunogenicity of a live attenuated mumps vaccine: a phase I clinical trial.

Authors:  Yan Liang; Jingchen Ma; Changgui Li; Yuguo Chen; Longding Liu; Yun Liao; Ying Zhang; Li Jiang; Xuan-Yi Wang; Yanchun Che; Wei Deng; Hong Li; Xiaoyu Cui; Na Ma; Dong Ding; Zhongping Xie; Pingfang Cui; Qiuyan Ji; JingJing Wang; Yuliang Zhao; Junzhi Wang; Qihan Li
Journal:  Hum Vaccin Immunother       Date:  2014-03-10       Impact factor: 3.452

7.  [Mumps in a urban area of the Community of Madrid. Vaccination status, diagnosis and intervention measures].

Authors:  R de los Ríos Martín; N García Marín; J Sanz Moreno; E Ballester Orcal
Journal:  Aten Primaria       Date:  2001-06-15       Impact factor: 1.137

8.  Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays.

Authors:  Jeremy Mauldin; Kathryn Carbone; Henry Hsu; Robert Yolken; Steven Rubin
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

9.  Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England.

Authors:  Cheryl Cohen; Joanne M White; Emma J Savage; Judith R Glynn; Yoon Choi; Nick Andrews; David Brown; Mary E Ramsay
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

Review 10.  Measles, mumps and rubella vaccine, autism and inflammatory bowel disease: advising concerned parents.

Authors:  David A C Elliman; Helen E Bedford
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.